Guangdong Marubi Biotechnology Co
Guangdong Marubi Biotechnology Co., Ltd. engages in the research and development, design, production, sale, and service of various cosmetics in China. The company provides skin care, make up, and eye care products. It offers its products under the Marubi, Lianhuo, Haruji, and the Love Fire brand names. The company was founded in 2002 and is based in Guangzhou, China.
Guangdong Marubi Biotechnology Co (603983) - Total Liabilities
Latest total liabilities as of September 2025: CN¥1.46 Billion CNY
Based on the latest financial reports, Guangdong Marubi Biotechnology Co (603983) has total liabilities worth CN¥1.46 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Guangdong Marubi Biotechnology Co - Total Liabilities Trend (2011–2024)
This chart illustrates how Guangdong Marubi Biotechnology Co's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Guangdong Marubi Biotechnology Co Competitors by Total Liabilities
The table below lists competitors of Guangdong Marubi Biotechnology Co ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Yduqs Participações S.A
SA:YDUQ3
|
Brazil | R$6.55 Billion |
|
Signature Bank
PINK:SBNYL
|
USA | $102.35 Billion |
|
Immix Biopharma Inc
NASDAQ:IMMX
|
USA | $11.82 Million |
|
Stendörren Fastigheter AB (publ)
ST:STEF-B
|
Sweden | Skr11.19 Billion |
|
DongKook Pharmaceutical Co. Ltd
KQ:086450
|
Korea | ₩293.92 Billion |
|
Clearpoint Neuro Inc
NASDAQ:CLPT
|
USA | $44.48 Million |
|
Jiangsu New Energy Development Co Ltd
SHG:603693
|
China | CN¥9.59 Billion |
|
New Providence Acquisition Corp. III Class A Ordinary Shares
NASDAQ:NPAC
|
USA | $12.86 Million |
Liability Composition Analysis (2011–2024)
This chart breaks down Guangdong Marubi Biotechnology Co's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.81 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.44 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Guangdong Marubi Biotechnology Co's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Guangdong Marubi Biotechnology Co (2011–2024)
The table below shows the annual total liabilities of Guangdong Marubi Biotechnology Co from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.62 Billion | +56.11% |
| 2023-12-31 | CN¥1.04 Billion | +23.44% |
| 2022-12-31 | CN¥838.64 Million | +39.04% |
| 2021-12-31 | CN¥603.19 Million | -24.07% |
| 2020-12-31 | CN¥794.44 Million | +3.66% |
| 2019-12-31 | CN¥766.40 Million | +4.27% |
| 2018-12-31 | CN¥735.02 Million | +14.31% |
| 2017-12-31 | CN¥643.00 Million | -0.74% |
| 2016-12-31 | CN¥647.79 Million | -0.32% |
| 2015-12-31 | CN¥649.88 Million | +8.77% |
| 2014-12-31 | CN¥597.49 Million | +22.90% |
| 2013-12-31 | CN¥486.14 Million | +3.47% |
| 2012-12-31 | CN¥469.82 Million | +4.65% |
| 2011-12-31 | CN¥448.94 Million | -- |